INVESTOR RELATIONS

Overview

  Sign up for email alerts:      

Silence At-A-Glance

Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercializing RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide.

 

Financial Snapshot

(SLN: LSE)


For an updated stock quote, please access the link above to the London Stock Exchange.
 

DOWNLOADS
        
 

Registrars 

Capita IRG plc
The Registry
34 Beckenham Road,
Beckenham, Kent, BR3 4TU
Tel: 020 8639 3399 
Fax:020 8639 2342  

 

 
2009 Annual Report and Meeting Notification
        
   
      Webcast - Corporate Update
Rodman & Renshaw 6th Annual Global Healthcare Conference
May 18, 2010
   
      Conference Call
2009 Year-End Preliminary Results
April 29, 2010


Latest News

19.08.10
Silence Therapeutics’ Partner Quark Signs Exclusive Option Agreement with Novartis for Development and Commercialisation of QPI-1002
11.08.10
Silence Therapeutics Adds New Patent to Industry Leading Structural Modification Intellectual Property Portfolio
14.07.10
Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
07.07.10
Silence Therapeutics Expands RNAi Structural Modification IP Portfolio with Issuance of New U.S. Patent
09.06.10
Silence Therapeutics Announces Issuance of New U.S. Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics
26.05.10
Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
more news +